Project overview
This double-blind randomized controlled trial evaluated the efficacy and safety of prophylactic tranexamic acid (TXA) in reducing perioperative blood loss during elective cesarean sections. A total of 76 ASA II parturients were divided into two groups: one receiving 1 g of intravenous TXA 10 minutes before skin incision, and the other receiving placebo. The primary outcome, mean hemoglobin-estimated blood loss (mHbEBL), was significantly lower in the TXA group (137.08 ± 216.56 mL) compared to the placebo group (517.79 ± 300.06 mL), with a p-value < 0.001. Hemoglobin drop at 48 hours postoperatively was also significantly less in the TXA group (mean 11.54 g/dL) than in controls (10.86 g/dL). No significant differences were noted between the groups in terms of vital signs, liver and renal function markers, or adverse effects, indicating that TXA did not compromise hemodynamic stability or organ function. These results demonstrate that pre-incision prophylactic TXA effectively minimizes blood loss without increasing perioperative risk.
This summary describes the research topic in our project library. Research findings belong to the authors; they are not outcomes of editorial support. Authors retain responsibility for their work.
Back to this project’s library page